Cambrex Karlskoga
Cambrex Karlskoga, a prominent subsidiary of Cambrex Corporation, is headquartered in Karlskoga, Sweden. Established in 1981, the company has become a key player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a strong focus on quality and compliance, Cambrex Karlskoga has achieved significant milestones, including certifications from regulatory bodies such as the FDA and EMA. The company offers a range of services, including custom synthesis and process development, which are distinguished by their commitment to innovation and efficiency. Cambrex Karlskoga's strategic location in Sweden allows it to serve a diverse clientele across Europe and North America, solidifying its position as a trusted partner in the pharmaceutical supply chain. With a reputation for excellence, Cambrex Karlskoga continues to contribute to advancements in drug development and manufacturing.
DitchCarbon Score
How does Cambrex Karlskoga's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cambrex Karlskoga's score of 41 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cambrex Karlskoga's reported carbon emissions
In 2023, Cambrex Karlskoga reported total greenhouse gas emissions of approximately 2,849,000 kg CO2e for Scope 1 and 2, alongside about 53,330,000 kg CO2e for Scope 3 emissions. This marks a reduction from 2022, where Scope 1 and 2 emissions were about 2,607,000 kg CO2e, and Scope 3 emissions were approximately 55,540,000 kg CO2e. Cambrex has set ambitious climate commitments, aiming for a 52% reduction in Scope 1 and 2 emissions by 2030, based on 2018 levels. Additionally, they target a 42% reduction in Scope 3 emissions by 2030, using 2020 as the baseline year. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit temperature rise to 1.5°C. The company is actively working towards these goals, demonstrating a commitment to sustainability within the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - |
| Scope 2 | - | - | - | - | - | - | - |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cambrex Karlskoga is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
